Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Slides:

Advertisements

Similar presentations

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

Advertisements

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Su K. Metcalfe, MD, MPH, Michael T

Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery David Palma, Otto.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Rebecca Muirhead, MBChB, MRCP, Stuart G

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer Hilâl Tekatli, MD, Niels Haasbeek,

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Joshua E. Rosen, BASc, Michelle C

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Detection of Lung Cancer by Automated Sputum Cytometry

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Volume 385, Issue 9962, Pages (January 2015)

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Nicholas Trakul, MD, PhD, Jeremy P

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD, Johan Vansteenkiste, MD, PhD,

Ethnic Differences in the Management of Lung Cancer in New Zealand

International Thymic Malignancies Interest Group: A Way Forward

Primary Small Cell Carcinoma of the Esophagus

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography.

Journal of Thoracic Oncology

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Stereotactic Body Radiotherapy for Central Lung Tumors

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer Cornelis J.A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J. Slotman, MD, PhD, Suresh Senan, MRCP, FRCR, PhD Journal of Thoracic Oncology Volume 6, Issue 12, Pages 2036-2043 (December 2011) DOI: 10.1097/JTO.0b013e31822e71d8 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1. Patient examples with early-stage non-small cell lung cancer (NSCLC) in central tumor locations: (A) tumor adjacent to the aortic arch, (B) tumor adjacent to the left ventricle, and (C) tumor in a hilar location, extending to the chest wall. The patient in panel (C) is the patient who developed a rib fracture after treatment. Journal of Thoracic Oncology 2011 6, 2036-2043DOI: (10.1097/JTO.0b013e31822e71d8) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2. Local, regional, and distant failure rates for central early-stage lung tumors after stereotactic ablative radiotherapy (SABR). Journal of Thoracic Oncology 2011 6, 2036-2043DOI: (10.1097/JTO.0b013e31822e71d8) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3. Overall survival for central and peripheral early-stage lung tumors after stereotactic ablative radiotherapy (SABR). Journal of Thoracic Oncology 2011 6, 2036-2043DOI: (10.1097/JTO.0b013e31822e71d8) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4. Biological effective doses (BED) tumor (α/β = 10) versus 2-year local control probability (A), and BED normal tissue (α/β = 3) versus severe toxicity (B), data derived from Table 4; present study marked by circle. BED, biologically effective dose; BED = D (1 + d/(α/β)), where D is total dose, d is dose per fraction, and the α/β ratio is assumed to be 10 for tumor tissue and 3 for normal tissues. Journal of Thoracic Oncology 2011 6, 2036-2043DOI: (10.1097/JTO.0b013e31822e71d8) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions